Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.
Pharmacokinetics Study of Donepezil HCl in Subjects Receiving Haemodialysis.
The purpose of this study is to investigate the pharmacokinetics of donepezil HCl 3 mg in
 subjects with end-state renal disease who were receiving haemodialysis.
This is a randomised, single-center, open-label, single-dose, two-period crossover
 pharmacokinetics study of donepezil HCl tablets 3 mg in subjects receiving haemodialysis.
 Subjects will be or will not be receiving haemodialysis. After intervals of over 15 days, the
 subjects will be receiving the other treatment.
Inclusion criteria:

 Subjects with end-stage renal disease who were receiving haemodialysis. Subject who are
 able and willing to give written informed consent.

 Exclusion criteria:

 Subjects with known hypersensitivity to drugs or foods. Subjects with a corrected QT
 interval greater than 450 msec at Screening period.